Literature DB >> 10319381

Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma).

B N Nathwani1, M R Drachenberg, A M Hernandez, A M Levine, K Sheibani.   

Abstract

Benign monocytoid B cells are seen in lymph nodes in different types of lymphadenitis and they occur in the form of clusters within and around sinuses and in the interfollicular areas, but rarely completely surround benign follicles to produce a marginal-zone pattern. The cytologic hallmark of these cells is the presence of abundant pale to clear cytoplasm; these cells usually are of medium size, and they have a rather bland-appearing, irregular nuclei with inconspicuous nucleoli. Malignant monocytoid B-cell proliferations in a lymph node have been classified as monocytoid B-cell lymphomas (MBCL), which are now called nodal marginal-zone B-cell lymphoma (MZL) in the World Health Organization (WHO) classification. In the recently published clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma, 25 of 1,378 cases (1.8%) were classified as primary MZL, whereas four times as many cases (105 or 7.6%) were classified as low-grade mucosa-associated lymphoid tissue (MALT)-type lymphoma. Transformation to large-cell lymphoma at the time of diagnosis was seen in five of 25 (20%) cases of nodal MZL and in 32 of 105 (30%) cases of MALT-type lymphoma. Comparison of the clinical findings at presentation and the survival results indicate that nodal MZL is more aggressive clinically than low-grade MALT-type lymphoma. For example, patients with nodal MZL had a significantly higher incidence of advanced-stage disease, including peripheral and paraaortic lymphadenopathy, than those with MALT-type lymphoma. Moreover, patients with nodal MZL had lower 5-year overall survival and failure-free survival than patients with MALT type lymphoma. When analysis was restricted to those patients with zero to three adverse risk factors in the International Prognostic Index, patients with nodal MZL still had a significantly lower overall and failure-free survival at 5 years than patients with MALT-type lymphoma. We conclude that nodal MZL is a distinctive disease entity and is similar to other low-grade nodal lymphomas, such as the follicular or small lymphocytic lymphomas, but different than MALT-type lymphoma.

Entities:  

Mesh:

Year:  1999        PMID: 10319381

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  6 in total

1.  Unique phenotypic profile of monocytoid B cells: differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma.

Authors:  F I Camacho; J F García; L Sánchez-Verde; A I Sáez; M Sánchez-Beato; M Mollejo; M A Piris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.

Authors:  L P Koh; L C Lim; C H Thng
Journal:  Med Oncol       Date:  2000-08       Impact factor: 3.064

3.  Colonic mucosa-associated lymphoid tissue lymphoma identified by chromoendoscopy.

Authors:  Sang-Wook Seo; Seung-Hwa Lee; Duck-Joo Lee; Kwang-Min Kim; Joon-Koo Kang; Do-Wan Kim; Jeong-Hun Lee
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.

Authors:  Jennifer R Brown; Jonathan W Friedberg; Yang Feng; Sarah Scofield; Kimberly Phillips; Paola Dal Cin; Robin Joyce; Ronald W Takvorian; David C Fisher; Richard I Fisher; Jane Liesveld; Diana Marquis; Donna Neuberg; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

Review 5.  Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.

Authors:  Michiel van den Brand; J Han J M van Krieken
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

Review 6.  Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors.

Authors:  Sung Yong Oh; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 3.165

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.